



Friday, November 18, 2022 (Black Bear Room)

- 2:00-2:10 Welcome (John Lewis, PhD.)- *Tribute Stewart Campbell and Arni Goodman.*
- 2:10-2:40 Introduction (John Lewis, PhD.)
- 2:40-3:00 New APCaRI initiatives - the next 5 years (Adam Kinnaird, MD., PhD.)

Biomarkers, Metastasis and Clinical Cohorts

- 3:00-3:50 KEYNOTE: "But what if....? Treatment regret in localized prostate cancer" Christopher Wallis, Assistant Professor, University of Toronto and Urologic Oncologist, Mount Sinai Hospital and University Health Network.
- 3:50-4:10 "Proteinase Signaling, Inflammatory Disease and Cancer", M.D. Hollenberg, D. Phil, MD, Professor, Departments of Physiology & Pharmacology, University of Calgary Cumming School of Medicine.
- 4:10-4:40 *Janssen Break*
- 4:40-5:00 "Economic Evaluation of Testing for Prostate Cancer Diagnosis in Alberta: PSA, Clarity DX®, and mpMRI", Charles Yan, Senior Principal Economist.
- 5:00-5:15 "PSA testing rates in indigenous vs. non-indigenous communities in Alberta" Alex Kiciak, MD.
- 5:15-5:30 "ClarityDx Bladder - Development Program", Argo Basu, PhD.

Imaging

- 5:30-5:50 "Advances in Ultrasound-Aided Biomarker Release and Virtual Histology for Prostate Cancer", Roger Zemp, PhD.
- 5:50-6:05 "Intravital imaging reveals complementary Wnt/b-catenin and Wnt/ATF2-dependent signaling activities during human tumour cell invasion and metastasis", Konstantin Stoletov, PhD.
- 6:05-6:20 "The Next Generation Trial – The first six months: Assessing 18F-PSMA-1007 positron emission tomography and magnetic resonance imaging in the primary staging of prostate cancer patients", Nikhile Mookerji, MD.
- 6:30-11:00 *Merck & AstraZeneca Dinner - Networking - Cash bar (Black Bear Room)*

Saturday, November 19, 2022 (Black Bear Room)

- 7:00-8:30 *Pfizer Breakfast Buffet (Carve Mountain Grill)*
- 8:30-8:50 Updates on Alberta PCa Cohorts: Registry & Biorepository, Anais Medina Martin, PhD
- 8:50-9:10 Future of Genetic Testing in Prostate Cancer within Alberta, Steve Yip, MD, MSc.

Proteomics, Genomics, and Prostate Cancer

Generously supported by:





Program
APCaRI Fall Symposium 2022
Nov. 18-19 2022, Banff Park Lodge

- 9:10-10:00 KEYNOTE: "The evolution of lethal prostate cancer" Paul Boutros, PhD., Data Scientist and Professor in the Departments of Human Genetics and Urology at the David Geffen School of Medicine at UCLA.
- 10:00-10:30 *Merck Break*
- 10:30-10:50 "Update of Proposed Molecular Platforms in Prostate Cancer Patients in Alberta", Tarek Bismar, PhD., Professor and Deputy Head, Dept of Pathology and Lab Medicine U Calgary Cumming School of Medicine
- 10:50-11:10 "Discovery of Proteomic and Proteogenomic Biomarkers of Prostate Cancer" Andrei P. Drabovich, PhD.
- 10:50-11:25 "Role of Zyxin in Gene Regulation and Cell Proliferation", M. Quadir Siddiqui, PhD.
- 11:25-11:40 "Clinical-Grade Comprehensive Genomic Profiling of Advanced/Metastatic Prostate and Bladder cancers", Pinaki Bose, PhD. Scientific Lead, Precision Oncology and Experimental Therapeutics (POET), Charbonneau Cancer Institute, University of Calgary, Co-Founder, VP Planning and Management, OncoHelix Inc.
- 11:40-11:55 "ARPC1B overexpression Is Significantly Associated with ERG/PTEN in Lethal Prostate Cancer and Its Inhibition Decreases Cell Invasion and Migration In Vitro", Yaser Gamallat, PhD.
- 11:55-1:30 *Bayer & Astellas Lunch & Team picture (Black Bear Room)*

Artificial Intelligence and Machine Learning

- 1:30-2:20 KEYNOTE: "How better software engineering improves scientific and medical research." Vijay Pandurangan, Prof. MSc., Adjunct Professor at Stanford School of Medicine.
- 2:20-2:40 Ross Mitchell. TBD
- 2:40-2:55 "Learning to Predict Prostate Cancer Recurrence from Tissue Images", Mahtab Farrokh, MSc.
- 2:55-3:10 "Evolution of the ClarityDX Prostate test: Optimizing test accuracy and costs", Robert Paproski, PhD.
- 3:10-3:25 *AstraZeneca Break*

Cancer Therapy & Imaging

- 3:25-3:45 "Outcomes of first subsequent taxane (FST) therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who received docetaxel intensification (DI) in metastatic castration-sensitive prostate cancer (mCSPC) as treated at the Cross Cancer Institute (CCI)." Gabrielle Robin, MD.
- 3:45-4:00 "The Alberta LINAC-MR P3 system", Arun Elangovan, MD.
- 4:00-4:15 Discussion, closing remarks, and adjournment

Executive and Science & Data Quality Committee meeting (Black Bear Room)

- 4:30-6:00 Executive Committee and Science and Data Quality Committee meeting
- 6:00-8:00 *Janssen Dinner for Executive Committee (La Terraza)*

Generously supported by:

